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Abstract
Introduction: Glaucoma is a sight-threatening retinal neuropathy associated with elevated intraocular pressure
(IOP) due to degeneration and fibrosis of the trabecular meshwork (TM). Glaucoma medications aim to reduce IOP
without targeting the specific TM pathology, Bone-marrow mesenchymal stem cells (MSCs) are used today in various
clinical studies. Here, we investigated the potential of MSCs therapy in an glaucoma-like ocular hypertension (OHT)
model and decipher in vitro the effects of MSCs on primary human trabecular meshwork cells.
Methods: Ocular hypertension model was performed by cauterization of 3 episcleral veins (EVC) of Long-Evans male
rat eyes. MSCs were isolated from rat bone marrow, amplified in vitro and tagged with quantum dot nanocrystals.
Animals were distributed as 1) MSCs group receiving 5.105cells/6μl Minimum Essential Medium and 2) MEM group
receiving 6μl MEM (n = 10 each). Injections were performed into the anterior chamber of 20 days-hypertensive eyes
and IOP was monitored twice a week for 4 weeks. At the end of experiment, cell distribution in the anterior segment
was examined in confocal microscopy on flat mounted corneas. Moreover, we tested in vitro effects of MSCs
conditioned medium (MSC-CM) on primary human trabecular meshwork cells (hTM cells) using Akt activation,
myosin phosphorylation and TGF-β2-dependent profibrotic phenotype in hTM cells.
Results: We demonstrated a rapid and long-lasting in vivo effect of MSCs transplantation that significantly
reduced IOP in hypertensive eyes induced by EVC. MSCs were located to the ciliary processes and the TM.
Enumeration of RGCs on whole flat-mounted retina highlighted a protective effect of MSCs on RGCs death. In vitro,
MSC-CM promotes: (i) hTM cells survival by activating the antiapoptotic pathway, Akt, (ii) hTM cells relaxation as
analyzed by the decrease in myosin phosphorylation and (iii) inhibition of TGF-β2-dependent profibrotic phenotype
acquisition in hTM cells.
Conclusions: MSCs injection in the ocular anterior chamber in a rat model of OHT provides neuroprotective effect in
the glaucoma pathophysiology via TM protection. These results demonstrate that MSCs constitute promising tool for
treating ocular hypertension and retinal cell degeneration.
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Introduction
Glaucoma is a neurodegenerative disease affecting ap-
proximately 70 million people worldwide, and is the
second leading cause of irreversible blindness. In contrast
to other degenerative eye diseases, glaucoma may appear
early in life, and consequently requires long-term ophthal-
mic medication. Primary open-angle glaucoma (POAG) is
characterized by a progressive retinal ganglion cells
(RGCs) death, which induces progressive loss in the visual
field and acuity. Elevation of the ocular pressure, the
major risk factor for RGCs death, occurs due to degener-
ation of the ocular tissue controlling aqueous humor out-
flow, namely the trabecular meshwork (TM). Indeed, TM
degeneration in glaucoma is associated with the loss of
TM cells, mainly through apoptotic mechanisms and oxi-
dative stress, as well as extracellular matrix (ECM) remod-
eling and accumulation [1, 2]. It also results from changes
in trabecular cell contractility associated with an increase
in transforming growth factor beta 2 (TGF-β2) in the
aqueous humor (AH) [3, 4]. These pathological changes
lead to an increase in AH outflow resistance that raises in-
traocular pressure (IOP) and subsequently affects the en-
tire neuronal visual pathway through RGCs degeneration
mechanisms [5]. Current therapies for POAG aim to
lower IOP by medication or surgery. However, these treat-
ments do not specifically target the pathologic mecha-
nisms involved in TM degeneration or in the RGCs
apoptosis. As a result, these intricate mechanisms could
explain some treatment failures in glaucoma. New thera-
peutic strategies that can encompass all facets of the disea-
se—IOP-lowering medications as well as neuro-protective
and TM-protective agents—are therefore still needed.
Mesenchymal stem cells (MSCs) are adult pluripotent
stem cells that today have become an attractive new tool
to treat various degenerative diseases. MSCs exist in all
organs and tissues [6], and have been characterized by
the expression of surface markers such as CD73, CD90,
CD29, and CD105 [7] and their ability to differentiate in
vitro into several cell types (i.e., osteoblasts, adipocytes,
chondroblasts, and fibroblasts) [7]. The efficacy of MSCs
therapy was originally attributed to the cells’ capacity to
restore a population of differentiated cells through trans-
differentiation [8]. However, MSCs also secrete a broad
range of bioactive factors that constitute their secretome,
which is responsible for the trophic (angiogenic, anti-
apoptotic, and organ-intrinsic precursor or stem cell
proliferation), immunomodulatory, anti-scarring, and
chemoattractant effects of MSCs [9, 10]. In neurode-
generative diseases, MSCs secrete neurotrophic factors
(such as brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), or vascular endothelial
growth factor (VEGF)), directly promoting neural cell
survival and cell growth or acting on the microenviron-
ment of the neural tissue [11]. Recently, several
preclinical studies using neurological disease models
confirmed the high value of MSCs as sources of factors
able to protect and promote tissue regeneration [12,
13]. In fact, cell-based therapies, such as gene-based
therapies, offer powerful therapeutic tools, but their
transfer to the clinical context remains difficult at times
depending on the disease and the tissue involved. These
new therapeutic means have found a convenient organ
with the eye because it is directly accessible to thera-
peutic interventions, protected from the systemic circu-
lation, and easy to examine so that drug efficacy and
side effects can be monitored [14].
MSCs have also been proposed for the treatment of ret-
inal diseases such as glaucoma [15], retinitis pigmentosa
[16], and age-related macular degeneration [17]. Using a
mouse ocular hypertension model, Manuguerra-Gagné et
al. [18] reported that MSCs injection into the anterior
chamber (AC) could induce TM regeneration and reacti-
vate local neural progenitors in the ciliary body pigmented
epithelium. However, this study did not examine the
molecular mechanisms of TM protection and the effect
on RGCs loss.
Here, we aimed to define the ability of bone marrow-
derived MSCs to reduce IOP and protect the integrity of
TM cells. Therefore, we first analyzed the impact of
MSCs intracameral injection on lowering IOP in a pre-
clinical model of ocular hypertension induced by episcleral
vein cauterization (EVC). To decipher the mechanisms
involved in the MSCs-dependent decrease in IOP, we per-
formed in vitro experiments to assess the effect of MSCs
with conditioned medium (MSC-CM) on primary human
trabecular meshwork (hTM) cell properties in terms of
viability, contractility, and expression of ECM compounds.
This MSCs therapy may offer a new way to promote tra-




Fifty male 8-week-old Long Evans rats weighing 300–350 g
were purchased from Janvier Laboratories (Le Genest-
Saint-Isle, France). Animals were kept in pathogen-free
conditions with food and water available ad libitum and
were housed in a 12-hour light/12-hour dark cycle. All
experiments were performed after evaluation and ap-
proval by the Institutional Animal Care and Use Com-
mittee, Comité d'éthique pour l’expérimentation animale
Charles Darwin (reference number: 03858.02), in accord-
ance with the guidelines from Directive 2010/63/EU of
the European Parliament on the protection of animals
used for scientific purposes. All procedures were per-
formed under anesthesia and all efforts were made to pre-
vent any pain.
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EVC ocular hypertension model
A surgical model of ocular hypertension was induced in
the right eye (RE) of each rat by cauterization of three
episcleral veins after conjunctival dissection under general
anesthesia—intraperitoneal injection of Ketamine 1000®
100 mg/kg (Virbac, Vauvert, France) and Xylazine 10 mg/
kg (Bayer HealthCare, Whippany, NJ, USA)—as reported
elsewhere [19]. The left eye (LE) underwent conjunctival
dissection only as a control. After surgery, IOP was moni-
tored every 5 or 6 days using a handheld tonometer
(TonoLab®; Medtronics, Jacksonville, FL, USA) without
sedation. Animals presenting low or unstable IOP during
a 21-day period after the surgery were excluded. Animals
were treated 21 days after the surgery and IOP was moni-
tored every 3–4 days for 24 other days in a blind manner.
Enzyme-linked immunosorbent assay
The concentrations of TGF-β2 in the AC of cauterized
eyes (REs) and contralateral eyes (LEs) were measured
using enzyme-linked immunosorbent assay (ELISA)
(DuoSet® DY302; R&D Systems, Minneapolis, MN,
USA). AHs were sampled from hypertensive eyes 21
days after surgery and pooled to obtain at least 50 μl per
assay. Ninety-six-well plates were coated overnight with
mouse anti-TGF-β2 capture antibody, and then nonspe-
cific binding was blocked for 2 hours with blocking buffer.
Samples of AH or serial dilutions of standards of rat
recombinant TGF-β2 were incubated for 2 hours, washed,
and then incubated with anti-TGF-β2 detection antibody
for 2 hours, followed by a 20-minute incubation period
with horseradish peroxidase-conjugated streptavidin. Re-
action product was detected using color reagent. The
color absorbance was read (450–570 nm, Infinite1000®;
TECAN, Männedorf, Switzerland) and averaged from 10
measurements per well.
MSC isolation and conditioned medium collection
Bone marrow was obtained from femur cavities of 8-week-
old Long Evans rats (Janvier Laboratories) after flushing in
minimal essential medium (αMEM), 10 % fetal calf serum
(FCS), and 1 % penicillin/streptomycin (PS) (Invitrogen,
Carlsbad, CA, USA). Cells were incubated in 75 cm2 flasks
(200,000 cells/cm2) at 37 °C in 5 % CO2 humidified air. Non-
adherent cells were discarded after 72 hours and MSCs were
then routinely cultured until their use at passage 4 and char-
acterized as shown in Additional file 1. MSCs were main-
tained in culture for a longer period until losing the CD73
specific marker as controlled by flow cytometry (passage 7,
data not shown), defining differentiated MSCs (dMSCs).
At near confluence, the cell monolayer was washed be-
fore adding either serum-free Dulbecco’s modified Eagle’s
medium (DMEM) + 1 % PS or serum-free Neurobasal®
medium containing 2 mM L-glutamine, 1 % gentamycin
(Invitrogen) for 24 hours. Supernatant was collected,
centrifuged at 1200 rpm for 2 minutes, and stored at −80 °
C until further use for experiments on hTM (CliniS-
ciences, Nanterre, France) and primary RGCs.
MSC injection and tracking system
Before injection, MSCs were washed with phosphate buf-
fer solution (PBS), trypsinized, and labeled with Quantum
Dot (QD) Fluorescent Nanocrystals (Qtracker® 655 Cell
Labeling kit; Invitrogen). Cells were suspended in αMEM
for each injection (5 × 105 MSCs/6 μl). Cell suspension
was checked under fluorescent microscopy for QD inte-
gration into MSCs.
MSCs were injected into the AC 21 days after EVC.
IOP was measured every 3–4 days for 24 days in both
eyes of each animal randomly distributed into four
groups: hypertensive eyes injected with 6 μl MEM
(EVC + MEM; n = 10); hypertensive eyes injected with
6 μl of 5 × 105 MSCs suspension (EVC + MSCs; n =
12); hypertensive eyes injected with 6 μl of 5 × 105
dMSCs suspension (EVC + MSCs; n = 5); and normo-
tensive eyes injected with 6 μl of 5 × 105 MSC suspen-
sion (MSCs; n = 5).
During injection, animals were maintained under gen-
eral anesthesia using isoflurane inhalation (induction 5
%, then 2 %). The injection was performed through a glass
capillary (TransferTip®; Eppendorf, Hauppauge, NY, USA))
under a binocular surgical microscope (Leica F18; Leica
Microsystems, Nanterre, France).
Immunostaining
At the end of the experiments, the animals were eutha-
nized and the eyes were immediately removed, fixed in
4 % paraformaldehyde for whole flat-mounted cornea
and retina microdissections, or embedded in an optimal
cutting-temperature compound for snap-freezing (OCT,
Tissue-Tek; Bayer Diagnostic, Puteaux, France). Retinas
were incubated for 2 hours in a blocking-permeabilizing
solution of PBS containing 10 % bovine serum albumin
(BSA) (Vector Labs, Burlington, ON, Canada), 2 % Triton
and 0.5 % Tween20 (Sigma-Aldrich, St. Louis, MO, USA).
Samples were incubated for 3 days at 4 °C with unlabeled
mouse anti-Brn3a 1/100 (Merck, Darmstadt, Germany),
washed with PBS six times for 20 minutes, and mounted
in Fluoromount™ (Sigma-Aldrich).
To visualize QD-labeled MSCs using fluorescent mi-
croscopy, flat-mounted corneas and eye cryosections (12
μm thick) were incubated in the blocking-permeabilizing
solution (10 % BSA, 2 % Triton, and 0.5 % Tween20)
before actin fibers and nuclei staining with Phalloidin
(Life Technologies, Carlsbad, CA, USA) and 4′,6′-diami-
dino-2-phénylindole (DAPI) (Vectashield; Vector Labs,
Burlingame, CA, USA) respectively. Whole flat-mounted
retina and cornea were scanned with the Hamamatsu
Nanozoomer Digital Pathology (Hamamatsu Photonics,
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Tokyo, Japan). Magnifications were performed with a
laser-scanning confocal microscope (FV1000; Olympus,
Philadelphia, PA, USA). Acquisitions were conducted
using the Olympus Fluoview software version 4.1.
Western blot analysis
Cell monolayers were homogenized in lysis buffer (25 mM
Tris pH 7.5, 150 mM NaCl, 0.5 % sodium deoxycholate,
1 % Triton, 0.1 % SDS) with a protease and phosphatase
inhibitor cocktail (Sigma-Aldrich). Cell homogenates
were centrifuged (10,000 rpm, 10 minutes, 4 °C). Pro-
tein concentrations were measured using Bradford re-
agent (Sigma-Aldrich). Equal amounts of total protein
were denatured for 10 minutes at 95 °C (5 μg) with
NuPage reducing agent (Invitrogen) before electrophoresis
in 4–12 % Tris-Glycine gel (Novex; Invitrogen); the mem-
branes were transferred to nitrocellulose, blocked with
TBS–Tween 0.1 % + Blotting Grade blocker 5 % (Bio-Rad,
Hercules, CA, USA) at room temperature for 2 hours, and
probed overnight at 4 °C with antibodies against β-actin
(1:10,000; Sigma-Aldrich), phospho-Akt (p-Akt) (1:500;
Cell Signaling, Danvers, MA, USA) and phospho-myosin
(p-MLC) (1:500; Cell Signaling). The membranes were
washed three times with TBS–Tween 0.1 % and incu-
bated for 30 minutes with the appropriate peroxidase-
conjugated secondary antibody (1:10,000). Cells were
detected using an enhanced chemiluminescence reaction
using ECL Plus detection reagents (GE Healthcare, Orsay,
France). Protein bands were quantified by densitometry
using ImageJ software (NIH, Bethesda, MD, USA) and the
results expressed as the protein of interest/β-actin ratio.
Real-time PCR
Total mRNA from cell monolayers was extracted using the
NucleoSpin RNA II extraction kit (Macherey-Nagel, Düren,
Germany). RNA content was measured using a NanoDrop
detector (ND-1000 spectrophotometer; Wilmington, DE,
USA); cDNA was synthesized from equal amounts of RNA
(800 ng) using Multiscribe reverse transcriptase (TaqMan
Reverse Transcription Reagents; Applied Biosystems, Life
Technologies, Carlsbad, CA, USA). Sample concentra-
tions were adjusted to 5 ng/μl cDNA. The reaction mix-
ture containing 25 ng cDNA per well was preheated at 95
°C for 10 minutes, followed by 40 cycles (95 °C for 15 sec-
onds and 60 °C for 1 minute). Each assay, carried out in
triplicate, was normalized by amplifying the house-
keeping cDNA hypoxanthine guanine phosphoribosyl-
transferase (HPRT) (ID Hs02800695;). Target cDNA
was amplified using the 7300 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA) with
assays-on-demand primers for human alpha-smooth
muscle actin (α-SMA) (ID Hs00426835m1), type III
collagen (ID Hs00943809), and type IV collagen (ID
Hs00266237; Applied Biosystems). Relative quantification
of target mRNA was assessed according to the compara-
tive Ct method (2–ΔΔCt); results are presented as the rela-
tive fold change compared with unstimulated control.
Human trabecular cell culture and treatment
This study used commercial hTM primary cells (ref.
6590-SC; CliniSciences) and did not use any material
taken from patients, so no consent was needed.
hTM cells were obtained from 24-year-old adult
donors. Cells were maintained in culture at 37 °C in an
atmosphere of 95 % air and 5 % CO2 in DMEM + 10 %
heat-inactivated (56 °C, 60 minutes) FCS + 1 % PS.
After trypsinization, 105 hTM cells were seeded in six-
well plates and tested in different conditions: serum-free
DMEM (Control), 20 ng/ml exogenous TGF-β2 (TGF-β2),
MSC-CM, or association of TGF-β2 (20 ng/ml) and MSC-
CM (TGF-β2 + MSC-CM). After washing, proteins were
recovered 3 hours after treatment, whereas RNA was
recovered 72 hours after treatment, with the adapted buf-
fer, as described previously.
hTM luminescent viability assay
After trypsinization, 105 hTM cells were seeded in 96-well
plates. Cells were exposed 24 hours later to an increasing
concentration of benzalkonium chloride (BAC) (Santen
Pharmaceutical) from 1.5 × 10−4 % (0.5 μM) to 5 × 10−4 %
(1.5 μM) for 24 hours. In each well, half the volume of cul-
ture medium was removed and replaced by CellTiter-Glo®
reagent (CTG) (Promega, Madison, WI, USA). Ten minutes
after adding CTG, the luminescent signal was measured by
spectrophotometry (Infinite1000®; TECAN, Männedorf,
Switzerland) to quantify the adenosine triphosphate (ATP)
content as an average from nine measurements per well.
Quantification of RGCs in whole flat-mounted retina
Eight microscopic images were captured using a 20×
objective of the peripheral and central area in whole flat-
mounted retina labeled with brain-specific homeobox/
POU domain protein 3A (Brn3a) antibody with a Zeiss
fluorescence microscope (Carl Zeiss SpA, Arese, Milan,
Italy) equipped with a digital camera (Axio Cam HRC;
Carl Zeiss) and image acquisition software (AxioVision;
Carl Zeiss). Automatic quantification of RGC nuclei was
assessed in a blind manner with MetaMorph software
(Universal Imaging, West Chester, PA, USA).
Statistical analysis
Values are expressed as mean ± standard error of the
mean. ELISA, western blot (WB), and quantitative RT-
PCR data were analyzed using the one-way or two-way
analysis of variance test followed by the post-hoc test
and nonparametric Mann–Whitney U-test. Statistical
analyses were performed using GraphPad Prism version
6.03 (GraphPad, San Diego, CA, USA). All statistical
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tests were two-sided and performed at the significance
level of p <0.05.
Results
Ocular hypertension model validation: effects on IOP and
AH TGF-β2 levels
An increase in the IOP levels is the main risk factor for
the development of glaucoma [20] and is correlated with
an increase of TGF-β2 in the AH [20]. We therefore
examined whether our animal model of glaucoma was
associated with an increase in AH TGF-β2 as the IOP
increased. Cauterization of three episcleral veins induced
a decrease in AH outflow and consequently an increase
in IOP. Twenty-four hours after surgery, the mean IOP
elevation in the cauterized eyes (REs) versus the contra-
lateral eye (LE) was 8.5 ± 2.8 mmHg (n = 5; p <0.001)
(Fig. 1a). IOP remained stable for approximately 6 weeks
with an overall mean increase of 10.4 ± 2.0 mmHg in
the RE vs. LE over this period of time (Fig. 1a). More-
over, the AH concentration of TGF-β2 showed a signifi-
cant twofold increase in the RE compared with the LE
(p <0.05) (Fig. 1b).
MSCs transplantation decreases IOP in a rat model of
ocular hypertension
To assess the therapeutic potential of MSCs in glau-
coma, we evaluated the intracameral injection of MSCs
in our model. Two days after the MSCs injection, the
IOP level in the EVC + MSCs group decreased by 5.1
mmHg, showing a significant difference compared with
the glaucomatous rats injected with a MEM control so-
lution (EVC + MEM group) (n = 10; p <0.01). The
MSCs-induced decrease in IOP remained significantly
different from the EVC + MEM group for 13 days
(Fig. 2a) (n = 10; p <0.05 and p <0.01). To examine
whether this IOP decrease was specific to the glau-
comatous condition, we also injected MSCs into control
rats having a normal ocular pressure (MSC group). The
IOP monitoring after the injection did not show any
modification in IOP during the experiment in this group
(Fig. 2a). Furthermore, to ensure that the injection of
biological material could participate in the IOP decrease,
5 × 105 dMSCs (EVC + dMSCs) were injected into
hypertensive eyes. No IOP modification was observed
(Fig. 2a), confirming the specific effect of nondifferen-
tiated MSCs on the IOP reduction.
The average of seven measurements of delta IOP (differ-
ence between cauterized RE and noncauterized LE), from
the time of injection to the day of sacrifice for each ani-
mal, was significantly lower in the EVC + MSCs group
than in the EVC + MEM group during this period.
Tracking MSCs in the AC after EVC
To investigate the origin of the IOP decrease induced by
MSCs injection, we examined the ocular distribution of
the MSCs after injection, in particular to determine
whether they were able to migrate into the TM and to
survive. For long-term tracing of the MSCs fate, we used
QD Fluorescent Nanocrystal labeling. Six rats were
injected with the labeled MSCs (5 × 105 MSCs). After
fixation of the tissues, the distribution of MSCs in the
AC was investigated in whole flat-mounted corneas.
Twenty-four days after the injection of 5 × 105 MSCs,
cells were found located near the iridocorneal angle, on
the corneal endothelium, and in the TM (Fig. 3a–c). The
higher magnification confirmed the intracellular integration
Fig. 1 Effect of EVC on IOP and AH TGF-β2 expression. Intraocular pressure (IOP) monitoring of right eyes (REs) exposed to three EVCs (black bar)
and of control left eyes (LEs; gray bar) over 44 days a. AH levels of transforming growth factor beta 2 (TGF-β2) of both cauterized (RE) and control
(LE) eyes sampled 21 days after EVC b. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001 vs. control
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of QD (Fig. 3c, ×800). Another set of six injected rats were
used for cryosectioning (Fig. 3d, e). As observed on flat-
mounted corneas, QD-labeled MSCs were found on the
corneal endothelium, on the iris, and in the TM but also in
the ciliary processes (Fig. 3e).
MSCs transplantation improves in vivo peripheral RGCs
survival
After confirmation of the beneficial effects of MSCs on
the IOP and their incorporation into the anterior struc-
tures of the eye, we investigated the effect of intracam-
eral MSC injection on RGCs degeneration. RGCs were
immunostained with Brn3a antibody in whole flat-
mounted retina. Images of the peripheral and central
areas of the retina were taken (Fig. 4a). No significant
effect was observed in the central retina on RGCs density
(Fig. 4b). However, the EVC + MEM group exhibited a sig-
nificant 33 % decrease (p = 0.016) in RGCs density in the
peripheral retina compared with the control group. Inter-
estingly, the RGCs density in the peripheral retina of the
EVC + MSCs group was significantly higher as compared
with the EVC + MEM group (p = 0.029) (Fig. 4c). The
density of RGCs in the peripheral retina of hypertensive
eyes treated with 5 × 105 MSCs was not significantly differ-
ent from the control normotensive noncauterized group
(LEs, p = 0.40). MSCs transplantation in the AC thus
appeared to protect from the peripheral RGCs degener-
ation in the EVC hypertension model.
MSC-CM induces TM primary cell survival and
contractibility
To further understand the IOP decrease following MSCs
injection, we investigated in vitro the impact of MSC-CM
on three major mechanisms described to be involved in
IOP regulation: TM cell viability, contractility, and TM
cell phenotype transition.
A previous study has shown a significant increase of
TM cell apoptosis in the hypertensive eyes induced by
EVC [19]. Thus, we first evaluated the effect of MSC-
CM on hTM cell viability using an in vitro cytotoxic
model. Cells are exposed for 24 hours to the cytotoxic
effects of BAC, which was found to induce TM cell death
in a dose-dependent manner. When co-applying MSC-
CM, we observed a significant shift in the lethal concen-
tration 50 (LC50) toxicity of BAC. LC50 was 6.3 × 10−6 M
for hTM cells alone instead of 7.8 × 10−6 M for hTM cells
maintained in MSC-CM (Fig. 5a). To confirm the benefi-
cial effect of MSC-CM on hTM cell viability, we examined
the activation by WB of a transduction factor involved in
survival mechanisms of Akt on hTM cells exposed to the
MSC-CM for 3 hours. We observed that hTM cells dis-
played a low level of Akt phosphorylation (p-Akt) in
control, whereas MSC-CM revealed a major increase
Fig. 2 MSC transplantation decreases IOP in a rat model of ocular hypertension. The intraocular pressure (IOP) was monitored in both cauterized
(right eye (RE)) and noncauterized (left eye (LE)) eyes. IOP measurements of the RE were reported for each animal per group: hypertensive eyes
injected with 5 × 105 MSCs (EVC + MSCs, green bar; n = 12), hypertensive eyes injected with culture medium alone (EVC + MEM, red bar; n = 10),
or normotensive eyes injected with 5 × 105 MSCs (MSCs, black bar; n = 5) a. Individual average of delta IOP (ΔIOP = RE IOP − LE IOP) measurements
from injection to sacrifice times were calculated and compared between the EVC + MSCs and EVC + MEM groups b *fp <0.05, **p <0.05, ***p <0.001
vs. EVC + MEM. dMSCs differentiated mesenchymal stem cells, EVC episcleral vein cauterization, MEM minimum essential medium, MSCs mesenchymal
stem cells
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in p-Akt corroborating the protective effect observed
in hTM cells exposed to the cytotoxic effect of BAC
(Fig. 5b).
TM cell contractility is associated with a resistance in
AH outflow. This mechanism involves TGF-β2, known
to be correlated with the IOP levels in AH of glaucoma
patients [13, 14] and described to trigger the phosphor-
ylation of the myosin fibers (MLC) inducing TM cell
contraction [21], reduction of HA outflow, and then
IOP increase. We exposed hTM cells to exogenous
TGF-β2 (20 ng/ml) for 3 hours in standard culture
medium ± MSC-CM. WB assays were performed to
detect and quantify MLC phosphorylation (Fig. 5c). In
this experimental condition, TGF-β2 triggered a twofold
increase in p-MLC (Fig. 5c). Interestingly, MSC-CM
strongly inhibited the effect of TGF-β2 on p-MLC in-
duction (Fig. 5c). In fact, hTM cells exposed simultan-
eously to TGF-β2 and MSC-CM showed a significantly
lower level of p-MLC than cells exposed to TGF-β2
alone.
For both markers, a beneficial effect was observed when
hTM cells were exposed to MSC-CM. Quantification of
the p-MLC and p-Akt bands were presented in histograms
(n = 4).
MSC-CM reduces trabecular mesenchymal transition in
primary trabecular cells
The third mechanism of TM degeneration implies TM
cell phenotype transition. TGF-β2 is known to induce
phenotype transition in different cell types (i.e., epithe-
lial, endothelial, or fibroblastic). This mechanism is
responsible for the initiation of tissue fibrosis even in
TM under glaucomatous conditions [22]. Therefore, we
investigated the potential protective effect of MSCs on
this trabecular mesenchymal transition (TMT) through
the analysis of genetic expression of two ECM com-
pounds, collagen-3 and collagen-4, and through a myofi-
broblast marker, α-SMA. First, we confirmed that hTM
cells exposed to TGF-β2 for 72 hours acquired an in-
creased mRNA expression of collagen-3 (Fig. 6a),
collagen-4 (Fig. 6b), and α-SMA (Fig. 6c). Then we
showed that this phenomenon was significantly reduced
when cells were simultaneously exposed to TGF-β2 and
MSC-CM. MSC-CM alone did not modify mRNA levels
Fig. 3 Tracking of MSCs after EVC in the AC. Whole flat-mounted cornea viewed with a digital fluorescence scanner (Nanozoomer) a. Confocal
microscopy images at two different magnifications (b ×200, c ×800) of flat-mounted cornea showing cell nuclei (DAPI; blue), actin fibers
(Phalloidin; green) and quantum dot (QD)-labeled MSCs (red) injected 21 days after EVC and found 23 days later at the time of sacrifice.
Representative images of AC angle with contrast phase d and fluorescence microscopy e showing cell nuclei (DAPI; blue) and QD-labeled
MSCs on the cornea endothelium, ciliary processes, and trabecular meshwork (TM) on a cryostat section (red).
DAPI 4′,6′-diamidino-2-phénylindole
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(Fig. 6a–c). MSC-CM inhibited the TGF-β2-dependent
phenotype transition in hTM cells.
Discussion
Since their identification by Friedenstein in the 1970s
[23], interest in bone marrow-derived MSCs in various
clinical contexts such as ischemic stroke [24], myocar-
dial infarction [9, 25], and Crohn’s disease [26] has
grown continuously. In the field of ocular diseases, bone
marrow-derived MSCs have successfully been proposed
to promote corneal healing [27–29], reduce dry eye in
chronic graft-versus-host disease [30], to prevent photo-
receptor degeneration [16, 17, 31], and also in glaucoma
to protect the RGCs from degeneration after intravitreal
injection [15, 32–35]. In this study, we originally show
that MSCs transplantation into the anterior segment of
the eye induces RGCs protection, through TM function
and integrity improvement and IOP reduction.
Cell-based therapeutic strategies for TM regeneration
have already been developed using induced pluripotent
stem cells or MSCs. Abu-Hassan et al. [36] showed in
an ex vivo perfused human AC model that induced
Fig. 4 MSCs transplantation improves RGCs survival. Whole flat-mounted retina immunolabeled with brain-specific homeobox/POU domain
protein 3A (Brn3a) antibody. Representative images (×200) of the peripheral or central area showing immunopositive staining of RGCs in
noncauterized (Control) and cauterized eyes injected with MEM (EVC + MEM) or MSCs (EVC + MSCs) a Quantification of central b and peripheral
c RGC densities per retina using automated nuclei counting in the control group (n = 5), EVC + MEM group (n = 5), and EVC + MSCs group
(n = 5). The average RGCs density was obtained from eight peripheral and central images per retina and per area. Data expressed as mean ±
standard error of the mean. *p <0.05 vs. control, #p <0.05 vs. EVC + MSCs. EVC episcleral vein cauterization, MEM minimum essential medium,
MSCs mesenchymal stem cells
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pluripotent stem cells are both able to repopulate the
degenerative TM and to acquire a TM cell morphology
and phenotype to finally restore the TM filtrating prop-
erty. The same conclusions have been reached with
MSCs derived from TM injected into a mouse AC.
Bone marrow-derived MSCs have also shown interesting
properties for TM regeneration. Manuguerra-Gagné et al.
[18] demonstrated a restoration of TM function after
MSCs injection into a mice model of laser-induced hyper-
tensive eyes. However, they demonstrated that MSCs
mainly acted though their paracrine activity stimulating the
resident TM stem cells. In fact, bone marrow-derived
MSCs did not acquire TM cell phenotype in coculture with
TM cells. Consequently, the interest of MSCs to fight TM
degeneration seems to come essentially from the factors
they secrete known to be involved in tissue homeostasis.
Therefore, in this study we focused on bone marrow-
derived MSC secretome potential to inhibit or alleviate
TM degeneration and to restore a filtering function.
Despite the description of many glaucoma models in the
literature (laser trabecular destruction, steroid-induced
ocular hypertension, intracameral injection of latex micro-
spheres, or autologous fixed red blood cells), there is still a
need for a more accurate glaucoma model. Because is it
difficult to reproduce lifelong progressive disease in
animals, the EVC model seems to be relevant to study
glaucoma therapeutic strategies. Many studies have char-
acterized and used the EVC model, which matched or
gathered many specific glaucoma features—not only an
IOP increase with a reduction of AH outflow without
affecting directly the TM, but also progressive RGCs
degeneration, an AH TGF-β2 level increase, and TM cell
death as observed in glaucomatous patients [3, 4]. Using
this EVC hypertension model, we showed that a single
Fig. 5 MSC-CM induces TM primary cell survival and contractility. Effect of MSC-CM on human trabecular meshwork (hTM) cell survival and
contractility with or without transforming growth factor beta 2 (TGF-β2). hTM cell viability assessed by ATP quantification following 24 hours of
increasing BAC concentration exposure with or without MSC-CM a. Immunoblot of phospho-Akt (p-Akt), ± MSC-CM, and phospho-myosin
(p-MLC), ± MSC-CM and ± TGF-β2, protein expression using WB in hTM cells was performed b, c. The relative density of protein bands were
quantified, and the ratios of phosphorylated protein to actin were calculated (n = 4) b, c. *p <0.05 and ***p <0.001 vs. control culture
condition, #p <0.01 vs. TGF-β2 condition. MSC-CM conditioned medium of mesenchymal stem cells
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injection of MSCs into the anterior segment of hyperten-
sive rat eyes is able to rapidly and significantly reduce the
increase in IOP induced by EVC. These results are in
agreement with Manuguerra-Gagné et al. [18] in another
preclinical ocular hypertension model in mice induced by
180° TM laser photocoagulation. Manuguerra-Gagné et al.
demonstrated recently that MSCs transplantation into
laser-induced hypertensive eyes of mice progressively
reduces IOP and attains a maximal effect at 10 days post
injection until the end of their 25-day study. In our study,
the IOP lowering was seen as soon as 3 days after injec-
tion and was maintained for 13 days. This difference could
be attributed to the different ocular hypertension animal
models used. Indeed, in the laser model half of the entire
TM was destroyed, compared with the EVC model in
which the TM was not directly damaged and the TM
injury was progressive and secondary to the increase in
IOP [19].
Twenty-three days after QD-labeled MSCs transplant-
ation, we demonstrated that MSCs were distributed within
the AC, especially inside and around the TM. These
results differ from those reported in Manuguerra-Gagné
et al.’s [18] study, in which MSCs were no longer detected
in the AC 96 hours post injection. These authors hypothe-
sized that the injected MSCs escaped through the TM or
died following their transplantation. QD staining is a more
adapted system for tracking this type of cell, because it is
able to show that MSCs remained integrated in the differ-
ent parts of the anterior segment of the eye for a long
period (at least 3 weeks) after injection into the AC.
While we demonstrated that MSCs were still present
in the tissue after 3 weeks, the reduction in IOP induced
by MSCs injection in the AC only lasted for approxi-
mately 2 weeks. We presumed that this transient MSCs
effect results in either tissue resistance to MSC-CM or
that the MSCs lose their ability to restore their tissue-
filtrating property. It is known that the effect of MSCs is
due to various molecules they synthesize and release.
Furthermore, they progressively differentiate into the tis-
sue type in which they are incorporated. Thus, we hypoth-
esized that injected MSCs progressively transdifferentiate
into specialized cells, which modify the nature of their
secretome and finally lose their positive effect on the TM.
The lack of effect on IOP observed with the injection of
dMSCs in the model (passage 7 in vitro loss of CD73
expression; data not shown) leads us to think that the IOP
reduction depends on MSCs pluripotent state.
Mechanisms involved in TM degeneration are still
poorly known. The size of this tissue does not help in-
vestigation of the in vivo features. However, studies have
highlighted major mechanisms involved in the loss of
TM function, especially a fibrotic process including TM
cell apoptosis and ECM remodeling and a defect in con-
tractility/relaxation of TM cells. The defects lead pro-
gressively to IOP increase. In an original manner, using
in vitro approaches, our work investigated whether
MSCs display valuable properties for these hallmarks.
TM cells are known to acquire contractile properties
in response to pharmacological stimulations. Specifically,
TM cell contraction has been reported to reduce AH
outflow, whereas TM cell relaxation increased AH out-
flow facility and thus decreased IOP [37, 38]. Using a
cellular TGF-β2-induced model of glaucoma, we showed
for the first time that MSC-CM prevented the TGF-β2-
dependent phosphorylation of myosin fibers on hTM
cells. The Akt pathway activation (a serine/threonine
kinase intracellular pathway involved in cell survival)
triggered by MSC-CM has already been observed in dif-
ferent kind of cells, like endothelial cells [39], fibroblasts
[40], or neurons [41]. We showed, first, that BAC ex-
hibits a cytotoxic effect on hTM cells at low concen-
tration (2 × 10−4 %; 0.7 μM); that is, approximately
Fig. 6 MSC-CM reduces epithelial mesenchymal transition-like phenomenon in primary trabecular cells. Effect of MSC-CM on transforming growth
factor beta 2 (TGF-β2) induced collagen-3 (COL-3) a, collagen-4 (COL-4) b, and alpha-smooth muscle actin (α-SMA) c mRNA modification on hTM.
The results are normalized to reference hypoxanthine guanine phosphoribosyltransferase (HPRT) genes. *p <0.01, **p <0.001, and ***p <0.0001 vs.
control culture condition; #p <0.05, ##p <0.01, ###p <0.001, and ####p <0.0001 vs. TGF-β2 condition; §p <0.01 and §§p <0.0001 vs. MSC-CM condition
(n = 5). MSC-CM conditioned medium of mesenchymal stem cells
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100 times less than in common glaucoma eye drops
(2 × 10−2 %; 70 μM). Secondly, we demonstrated that
MSC-CM induced Akt phosphorylation on hTM cells,
promoting efficiently their survival in a BAC-induced
cytotoxic in vitro model.
Growing interest is also focused on the TMT-like
phenomenon concerning trabecular cells [22]. Indeed, this
mechanism, occurring in chronic inflammatory disease, is
defined as initiating fibrosis in different tissues. Here, we
confirmed in human primary trabecular cells that exogen-
ous TGF-β2 was able to induce TMT through the increase
of ECM compound mRNA such as collagen-3, collagen-4,
and the myofibroblast marker α-SMA. As previously
shown in other fibrosis models in various tissues [42, 43],
we also observed that MSC-CM significantly reduced
collagen-3 and collagen-4. Moreover, the increase in α-
SMA mRNA induced by TGF-β2 confirmed that MSC-
CM could be useful to block TM fibrosis. Thus, we
showed the direct impact of MSC-CM in vitro on TM cell
survival, contractility, and the reduction of the profibrotic
phenotype. These MSC-CM specific effects on TM cells
in vitro could explain the rapid IOP decrease, even if tran-
sient, that occured after MSCs intracameral injection.
In glaucoma, the loss of vision is related to the degen-
eration of RGCs. RGCs protection after MSCs intravit-
real injection has been evidenced in different animal
models of retina degeneration such as optic nerve crush
[44] or optic tract transection [45] and ocular hyperten-
sion induced by photocoagulation of the TM [15]. More
recently, the same conclusion has been reached using
organotypic retina explant cultures [34]. In an in vitro
study, we could observe a direct trophic effect on a puri-
fied primary rat RGCs culture using a cell viability assay
(data not shown). Together, these studies showed that
MSCs played favorable effects either directly on RGCs
survival and outgrowth or indirectly by acting on the
RGCs microenvironment. Direct neuroprotective and/or
neuroregenerative therapeutic strategies constitute a
major challenge but, until today, they have not brought any
relevant clinical effects. Because ocular hypertension is the
most important risk factor for RGCs death in glaucoma, we
have innovatively demonstrated in this work that MSCs in-
jection into the AC of hypertensive eyes is able to greatly
reduce IOP resulting in an efficient protection of RGCs
from degeneration processes; this latter effect of IOP reduc-
tion protecting RGCs, as already demonstrated by others
[19]. In fact, the hypertensive eyes injected with MSCs
(EVC + MSCs) did not develop the significant loss of per-
ipheral RGCs (8 %, p = 0.40) that was observed in the EVC
+ MEM group (33 %, p = 0.016). RGCs density in the per-
ipheral retina was significantly higher in MSCs-injected
hypertensive eyes. Peripheral RGCs are known to be more
sensitive than central RGCs to high IOP, as shown by the
retinal damage characterization in the ocular hypertension
model [20, 46]. We suggest that the neuroprotective effect
observed here could be mainly due to the IOP decrease
that occurs after MSCs injection.
Conclusion
The rationale behind using MSCs in glaucoma is based
on pathophysiologic clues. First, the increase in TGF-β2
levels in the AH of glaucoma patients induces phenotype
changes through trabecular to mesenchymal transition
resulting in fibrotic-like mechanisms involving cell apop-
tosis and ECM remodeling. Further, the peripheral RGCs
death leading to progressive vision loss justifies the
potential therapeutic use of MSCs. MSCs therapy is
already used today, with promising therapeutic results,
at the preclinical and early clinical stages for various de-
generative/fibrotic diseases. Indeed, MSCs have already
demonstrated remarkable neuroregenerative and neuro-
protective functional effects in several central nervous sys-
tem disease models including clinical studies [11–13, 47].
The safe use of MSCs in autologous transplantations has
led to several clinical trials for acute (ischemic stroke,
spinal cord injury) or chronic (Parkinson’s disease) ner-
vous system diseases. The eye is particularly attractive in
that it has features which can rapidly advance cell therapy:
the eye is readily accessible for injection and allows direct
visualization and monitoring of the impact of therapeutic
interventions. Moreover, little or no side effects may occur
since local ocular administration of MSCs should not have
the same general impact related to systemic injections.
Lastly, in contrast to embryonic or fetal stem cells, the
safety profile of MSCs and the possibility of obtaining
MSCs from individual patients allowing autologous trans-
plantation would highly facilitate transfer to the clinic.
Despite all these advantages of MSCs therapy, many stud-
ies remain to be performed in order to define the cell-
based therapy parameters for preclinical pharmacokinetics
and toxicological studies—dose, biodistribution, safety
evaluations—and also to identify some major molecules
that could be involved in the positive effects observed in
vitro and in vivo and that could be candidates for thera-
peutic development. Overall, present results show that
MSCs are a promising tool for treating ocular hyperten-
sion and retinal cell degeneration. Such an innovative ap-
proach could therefore open many therapeutic avenues
based on MSCs therapy in glaucoma.
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